Does Affinity Health Plan Cover Semaglutide (Wegovy)?

Affinity Health Plan's Wegovy coverage rules are not publicly available, and we cannot verify the plan's current medical policy from external sources. What is documented: the FDA approved semaglutide 2.4 mg (Wegovy) in 2021 for chronic weight management in adults with obesity or overweight plus a weight-related condition, and nearly all New York Medicaid managed-care plans, including Affinity, require prior authorization for weight-loss drugs rather than automatic approval. Approval for an individual Affinity member depends on their specific plan type (Medicaid managed care, Essential Plan, or commercial coverage through an employer), where Affinity's pharmacy and therapeutics committee places the drug on its formulary, and the completeness of the prescriber's medical necessity documentation. This approval decision cannot be determined from publicly available databases and requires direct contact with Affinity at the time of the prescription.

Semaglutide, Wegovy, and Ozempic are not interchangeable for coverage purposes

Semaglutide is a GLP-1 receptor agonist available under two brand names, each with its own FDA-approved use. Wegovy, the 2.4 mg once-weekly injectable version, received FDA approval in June 2021 for chronic weight management in adults with a BMI of 30 kg/m² or higher, or 27 kg/m² or higher if they also have a weight-related condition like type 2 diabetes, hypertension, or dyslipidemia. Ozempic contains the same active ingredient at a lower maximum dose (up to 2.0 mg weekly) and is FDA-approved only for type 2 diabetes, not for weight loss. When Ozempic is prescribed for weight loss in someone without diabetes, it becomes an off-label use; insurers typically evaluate off-label prescriptions using different medical-necessity standards than they apply to FDA-approved Wegovy prescriptions. Identifying which product and which approved indication appears on the actual prescription forms the foundation for understanding how an insurance plan will evaluate it.

What is established, and what is not

Established (stable, not plan-dependent): Wegovy's FDA-approved indication, BMI thresholds, and boxed warning for a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 are fixed in the FDA-approved prescribing information and do not vary by insurer. Federal Medicaid managed-care rules give states latitude to require prior authorization for anti-obesity drugs, and New York State Medicaid has historically used that latitude. These facts come from the FDA label and CMS's managed-care rulemaking and are unlikely to change without a formal regulatory action.

Plausible but not confirmed for this specific plan: It is reasonable to expect that Affinity's Medicaid managed-care product mirrors New York State Medicaid's general obesity-pharmacotherapy criteria (BMI threshold, documented lifestyle intervention, absence of contraindications) because managed-care plans typically build their prior authorization criteria around the state's fee-for-service benchmark. That is an inference, not a confirmed fact about Affinity's current medical policy document.

Not established from the source material used here: The exact prior authorization turnaround time Affinity uses, the current formulary tier for Wegovy under Affinity's Essential Plan or commercial products, Affinity's specific denial and appeal language, and any specific copay or coinsurance amount a member would pay. None of these are things a general medical reference can state accurately, because insurers revise formularies and cost-sharing on their own schedules, sometimes multiple times a year.

How Affinity's plan products likely differ

Affinity Health Plan operates Medicaid managed care, Child Health Plus, and Essential Plan products, primarily in the New York City metropolitan area, plus administers benefits for some employer groups. These product lines are not interchangeable for drug coverage purposes.

For Medicaid managed-care members, coverage of anti-obesity medication is governed by New York State Medicaid policy and CMS managed-care rules, which permit but do not mandate prior authorization requirements for GLP-1 obesity drugs. For Essential Plan members, New York State has been updating Essential Plan benefits to move closer to Qualified Health Plan standards, but whether Wegovy sits on a given formulary tier in a given plan year is something only Affinity's current formulary document can answer. For employer-sponsored commercial coverage administered by Affinity, the Affordable Care Act does not require anti-obesity drug coverage, so the employer's benefit contract, not a general Medicaid standard, controls the outcome. Some employer plans carve out weight-loss drugs entirely.

Because these three pathways can produce three different answers for three different Affinity members, "does Affinity cover Wegovy" is really three separate questions, and the plan's member services line or the member's Evidence of Coverage document is the only reliable place to resolve them.

What a prior authorization request typically needs

Based on FDA labeling requirements and the general structure of Medicaid-aligned prior authorization criteria for anti-obesity drugs, a complete PA packet generally includes:

• Current BMI, measured at an in-person or telehealth visit, not self-reported
• A qualifying BMI (30 or higher) or a BMI of 27 or higher plus a documented comorbidity such as type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea
• Documentation of a prior attempt at structured dietary or behavioral intervention
• Confirmation that the boxed-warning contraindications (personal or family history of medullary thyroid carcinoma, MEN 2) are absent
• A dose titration plan consistent with the FDA label, which starts at 0.25 mg weekly and escalates over roughly 16 weeks to the 2.4 mg maintenance dose
• The prescriber's National Provider Identifier and confirmation that the prescriber is in-network with Affinity

This list reflects standard payer expectations for GLP-1 obesity prescriptions generally. It is not a guarantee of Affinity's exact PA form, and prescribers should use Affinity's own submitted criteria, available through the plan's provider portal, rather than relying on a generic checklist.

If Affinity denies the request

Federal Medicaid law and New York State managed-care rules require a written denial that states the clinical rationale and explains appeal rights. Standard appeal windows and expedited appeal rights for urgent situations exist under Medicaid managed-care regulation, but the exact number of days and the exact procedure are stated in the denial notice itself and should be confirmed there rather than assumed. If an internal appeal is unsuccessful, New York members generally have access to an external appeal process through the state Department of Financial Services or an independent review organization for medically necessary drug denials, though eligibility rules for that process should be confirmed with the state or the plan.

A strong appeal typically restates the FDA-approved indication and BMI criteria, documents any weight-related comorbidities in detail, and, where relevant, references established clinical trial evidence on semaglutide's effect on body weight and cardiovascular risk. Citing a specific effect size (for example, a percentage of body weight lost in a named trial) is persuasive only if the number is accurate; a clinician assembling an appeal should pull the figure directly from the published trial report or the FDA label rather than from a secondary summary, since misquoted statistics can undermine an otherwise strong appeal.

Cost and access if coverage is denied or delayed

Wegovy's list price has been widely reported in the range of roughly $1,300 to $1,350 per month as of 2024-2025, but list prices change and this figure should be verified against Novo Nordisk's current published price before being used in a financial decision. Manufacturer savings programs and patient assistance programs have existed for commercially insured and uninsured patients respectively, with eligibility rules (income thresholds, insurance status) that are set by the manufacturer and subject to change; check NovoCare's current program terms directly rather than relying on a fixed dollar figure.

Compounded semaglutide was available from some pharmacies while Wegovy was listed on the FDA drug shortage list. The FDA removed semaglutide injection from its shortage list in February 2024, a status that governs whether outsourcing facilities may legally compound copies of the FDA-approved product. Because FDA shortage determinations and enforcement posture can change, anyone considering compounded semaglutide should check the FDA's current shortage database before assuming availability. Tirzepatide (Zepbound), FDA-approved for chronic weight management in November 2023, is a separate molecule in the same drug class and may sit on a different formulary tier than Wegovy under a given Affinity product; this is a plan-specific fact, not a general one.

What to ask before your doctor submits anything to Affinity

A short benefits verification call to Affinity's pharmacy department, using the member's exact plan ID, the drug name, and the National Drug Code, can confirm the current formulary tier, prior authorization requirement, and expected cost-sharing before a prescription is even written. This single step resolves most of the uncertainty described above far more reliably than any general reference article can.

Verification checklist: stable facts vs. facts that expire

This information distinguishes between GLP-1 facts that remain constant and Affinity-specific details that require verification with Affinity, New York State Medicaid, your pharmacy, or the manufacturer before finalizing any coverage or cost expectations.

Stable, federal or clinical facts (do not vary by plan or change often)

• Wegovy (semaglutide 2.4 mg) is FDA-approved for chronic weight management in adults with BMI ≥30, or ≥27 with a weight-related comorbidity, confirm against the current FDA label
• Wegovy carries a boxed warning for personal or family history of medullary thyroid carcinoma or MEN 2
• Ozempic (semaglutide, diabetes indication) and Wegovy (semaglutide, obesity indication) are the same molecule with different approved uses and different dosing
• States retain authority under federal Medicaid managed-care rules to require prior authorization for anti-obesity drugs
• FDA shortage status for semaglutide can be checked at any time on the FDA drug shortage database

Date-sensitive, plan- or market-specific facts (verify before relying on them)

• Whether Wegovy is on Affinity's current formulary for your specific product (Medicaid managed care, Essential Plan, or commercial), call Affinity or check your Evidence of Coverage
• Affinity's current prior authorization criteria and required documentation, request the current PA form from Affinity's provider portal
• Affinity's current appeal timelines and process for your product, read the specific denial notice, which is legally required to state them
• Wegovy's current list price and any manufacturer savings card or patient assistance eligibility rules, check NovoCare's current published terms
• Current FDA compounding enforcement status for semaglutide, check the FDA shortage page before assuming a compounded product is available
• Formulary placement of alternatives such as tirzepatide (Zepbound) under your specific Affinity product

When to seek care rather than rely on this article

If you experience symptoms of pancreatitis (severe abdominal pain), signs of a thyroid mass or a persistent hoarse voice, or a severe allergic reaction while taking semaglutide, seek medical care rather than waiting for a coverage decision. Coverage and cost questions are administrative; symptoms that could indicate a medication complication are not, and a pharmacy benefits call should never delay evaluation of a possible adverse effect.